ARGX vs UTHR
argenx SE vs United Therapeutics — AI-powered side-by-side comparison
VS
UTHR
United Therapeutics
72
Buy
| Metric | ARGX | UTHR |
|---|
| AI Score |
69
|
72
|
| Price |
$864.40
|
$514.89
|
| P/E Ratio |
31.34×
|
17.05×
|
| ROE |
17.6%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
86.1%
|
| Debt / Equity |
0.01×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
47.9
|
52.2
|
| Beta |
-0.022
|
0.564
|
| Expected Upside |
—
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for ARGX versus UTHR.
UTHR leads by 3 points.
UTHR scores 72/100 (Buy) versus ARGX at 69/100 (Buy).
ARGX Committee View
67% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 13.5% downside vs 6.4% upside.